DCC and cancer: First, the overall mutation rate of netrin1 receptors in the pan-cancer survey was 7%–35% (Fig. 2e), in which DSCAM (35%), DCC (33%), and UNC5D (20%) showed higher mutation rates and these mutations occurred in highly malignant endometrial cancer and skin melanoma.